Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $537K fell 20.4% year over year, behind the -9.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at -71.8% a year.

Context

  • Cost of revenue amounted to 191.0% of revenue in FY2025, down 951.5 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -20.4% toward the trailing-twelve-month pace of -9.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$537K-4.8% QoQ
Last fiscal yearDec 2025
$2.48M+8.7% YoY
LTMMar 2026
$2.35M-9.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.4%——
1 year+8.7%——
3-year CAGR-71.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.48M USD
Year-over-year change
+8.7%
4-year CAGR
-2.0%

Cost of Revenue vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.8% is the highest of 5, against a peer median of -89.6%.
  • Cost of revenue amounts to 180.4% of revenue for INBX, versus a peer median of 45.9%.
INBX Competitors
Cost of Revenue for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABSIAbsci CorporationLTM Mar 2026$26.01M USD-49.9%-41.6%1416.9%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M USD-79.7%+34.1%45.9%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$2.35M USD-9.8%-71.8%180.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K USD-99.5%—762.5%
GENBGenerate Biomedicines, Inc.FY2025$0 USD——0.0%
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$0 USD———
Peer median (excluding INBX) —-89.6%-3.7%45.9%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.